{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:32:15Z","timestamp":1781757135790,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Infect Dis."],"published-print":{"date-parts":[[2015,4,1]]},"DOI":"10.1093\/infdis\/jiu576","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T06:05:29Z","timestamp":1414649129000},"page":"1144-1153","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible<i>Streptococcus pneumoniae<\/i>"],"prefix":"10.1093","volume":"211","author":[{"given":"Ron","family":"Dagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noga","family":"Givon-Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurith","family":"Porat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"2016042507513855000_211.7.1144.1","first-page":"93","article-title":"Pneumococcal conjugate vaccine for childhood immunization--WHO position paper","volume":"82","author":"World Health Organization","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"2016042507513855000_211.7.1144.2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir755"},{"key":"2016042507513855000_211.7.1144.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.091"},{"key":"2016042507513855000_211.7.1144.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-012-0260-x"},{"key":"2016042507513855000_211.7.1144.5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit315"},{"key":"2016042507513855000_211.7.1144.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051642"},{"key":"2016042507513855000_211.7.1144.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.020"},{"key":"2016042507513855000_211.7.1144.8","doi-asserted-by":"publisher","DOI":"10.1086\/597044"},{"key":"2016042507513855000_211.7.1144.9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10158782.2011.11441462","article-title":"The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci","volume":"26","author":"Nzene","year":"2011","journal-title":"South Afr J Epidemiol Infect"},{"key":"2016042507513855000_211.7.1144.10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit428"},{"key":"2016042507513855000_211.7.1144.11","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02199-06"},{"key":"2016042507513855000_211.7.1144.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.056"},{"key":"2016042507513855000_211.7.1144.13","unstructured":"NCCLS Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Wayne, PA: Clinical and Laboratory Institute; 2008. Document M100-S18."},{"key":"2016042507513855000_211.7.1144.14","unstructured":"CDC. Pneumococcal disease: drug resistance. Atlanta, GA: Centers for Disease Control and Prevention; http:\/\/www.cdc.gov\/pneumococcal\/drug-resistance.html Accessed 11 April 2014."},{"key":"2016042507513855000_211.7.1144.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)00938-7"},{"key":"2016042507513855000_211.7.1144.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3099"},{"key":"2016042507513855000_211.7.1144.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)01280-6"},{"key":"2016042507513855000_211.7.1144.18","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e328341d1f5"},{"key":"2016042507513855000_211.7.1144.19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-69"},{"key":"2016042507513855000_211.7.1144.20","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800056648"},{"key":"2016042507513855000_211.7.1144.21","unstructured":"Juergens C Patterson S Trammel J . Functional antibody responses to 13-valent versus 7-valent pneumococcal conjugate vaccine (PCV13; PCV7): a randomized, double-blind trial. Presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan, Italy. 2013."},{"key":"2016042507513855000_211.7.1144.22","doi-asserted-by":"publisher","DOI":"10.1086\/431679"},{"key":"2016042507513855000_211.7.1144.23","doi-asserted-by":"publisher","DOI":"10.1038\/nri2508"},{"key":"2016042507513855000_211.7.1144.24","first-page":"129","article-title":"Pneumococcal vaccines, WHO position paper \u2013 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"2016042507513855000_211.7.1144.25","unstructured":"Dagan R Givon-Lavi N Greenberg D . A prospective study to evaluate Streptococcus pneumoniae nasopharyngeal acquisition (SPNA) in the first 30 months of life following a 3-dose primary pneumococcal conjugate vaccine (PCV7) regimen: Effect of a booster dose at 12 months of age. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA,. 2009."},{"key":"2016042507513855000_211.7.1144.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.112"},{"key":"2016042507513855000_211.7.1144.27","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318275614b"},{"key":"2016042507513855000_211.7.1144.28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/INF.0b013e3182748ada","article-title":"The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial","volume":"32","author":"Singleton","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2016042507513855000_211.7.1144.29","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182787f89"},{"key":"2016042507513855000_211.7.1144.30","doi-asserted-by":"publisher","DOI":"10.3201\/eid1907.121830"},{"key":"2016042507513855000_211.7.1144.31","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0047-z"},{"key":"2016042507513855000_211.7.1144.32","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31827e8594"},{"key":"2016042507513855000_211.7.1144.33","unstructured":"Angoulvant F Levy C Varon E . Pneumococcal pneumonia in children: a French prospective study in the era of 13 valent pneumococcal conjugate vaccines implementation in France. Presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan, Italy. 2013."},{"key":"2016042507513855000_211.7.1144.34","unstructured":"Diel M Laurenz M Krause K . Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany. Presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan, Italy. 2013."},{"key":"2016042507513855000_211.7.1144.35","unstructured":"Simonson L Klugman K Taylor RJ Schuck C Lustig R Haber M . Reductions in invasive and non-invasive pneumo-related US hospital admissions only two years after PCV13 introduction: evidence of substantial direct and indirect (herd) benefits. Presented at: IDWeek; San Francisco, CA,. 2013."},{"key":"2016042507513855000_211.7.1144.36","unstructured":"Dagan R Greenberg D Leibovitz E Raiz S Givon-Lavi N . Trends in serotype-specific pneumococcal carriage in children visiting emergency room (PER) post PCV7 and PCV13 introduction correlate with trends in serotype-specific otitis media incidence (OM). Presented at: IDWeek; San Francisco, CA,. 2013."},{"key":"2016042507513855000_211.7.1144.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2013.12.028"},{"key":"2016042507513855000_211.7.1144.38","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318247ef84"},{"key":"2016042507513855000_211.7.1144.39","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.5.5.651"},{"key":"2016042507513855000_211.7.1144.40","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.53"}],"container-title":["Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/211\/7\/1144\/13806218\/jiu576.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T22:30:21Z","timestamp":1650493821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jiu576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,3,10]]},"published-print":{"date-parts":[[2015,4,1]]}},"alternative-id":["10.1093\/infdis\/jiu576"],"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiu576","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}